Published in Eur J Immunol on March 14, 2011
Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Biochim Biophys Acta (2014) 1.02
A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis. Proc Natl Acad Sci U S A (2012) 0.93
OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses. Immunol Rev (2011) 0.82
MNT and Emerging Concepts of MNT-MYC Antagonism. Genes (Basel) (2017) 0.75
A novel role for the extended MYC network in cancer cell survival. Mol Cell Oncol (2015) 0.75
CRM1 is an export receptor for leucine-rich nuclear export signals. Cell (1997) 18.60
The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol (2000) 8.47
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody. J Exp Med (1983) 7.55
The B7 and CD28 receptor families. Immunol Today (1994) 6.38
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev (2004) 5.83
Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med (1994) 5.60
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell (1993) 5.28
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (2001) 4.46
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell (1993) 4.10
c-myc oncogene protein synthesis is independent of the cell cycle in human and avian cells. Nature (1985) 3.72
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
Sin meets NuRD and other tails of repression. Cell (1999) 3.31
Myc and Max associate in vivo. Genes Dev (1992) 3.16
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity (2001) 3.08
Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol (1998) 2.74
A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev (1993) 2.65
Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J (1985) 2.53
Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc-dependent pathway. Nat Immunol (2001) 2.36
CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. J Immunol (1998) 2.01
Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev (1997) 1.96
Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res (2003) 1.91
CD28/B7 costimulation: a review. Crit Rev Immunol (1998) 1.87
During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J Immunol (2005) 1.81
Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene (2001) 1.78
Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res (2000) 1.73
Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A (2008) 1.69
Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol (1999) 1.69
Multiple mechanisms regulate c-myc gene expression during normal T cell activation. EMBO J (1988) 1.66
Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol (2002) 1.50
Intrathymic proliferation wave essential for Valpha14+ natural killer T cell development depends on c-Myc. Proc Natl Acad Sci U S A (2009) 1.50
Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur J Immunol (2008) 1.48
Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells. Mol Cell Biol (2004) 1.47
Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol (2000) 1.45
T cell co-stimulatory molecules other than CD28. Curr Opin Immunol (1999) 1.43
OX-40: life beyond the effector T cell stage. Semin Immunol (1998) 1.43
An extended bipartite nuclear localization signal in Smad4 is required for its nuclear import and transcriptional activity. Oncogene (2003) 1.29
Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol (2005) 1.25
Costimulation of CD8 T cell responses by OX40. J Immunol (2004) 1.24
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol (2007) 1.24
Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immunol (2001) 1.23
OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J Immunol (2005) 1.22
The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression. Immunity (2004) 1.22
Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol (2006) 1.21
4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol (2004) 1.16
IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol (2008) 1.14
Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol Cell Biol (2004) 1.13
CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J Exp Med (2004) 1.12
Targeted deletion of the S-phase-specific Myc antagonist Mad3 sensitizes neuronal and lymphoid cells to radiation-induced apoptosis. Mol Cell Biol (2001) 1.09
Inhibition of proliferation and apoptosis by the transcriptional repressor Mad1. Repression of Fas-induced caspase-8 activation. J Biol Chem (2000) 1.07
OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. J Immunol (2003) 1.06
Beyond calcium: new signaling pathways for Tec family kinases. J Cell Sci (2002) 1.05
Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest (2006) 1.05
The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J Leukoc Biol (2004) 1.01
Reversible activation of c-Myc in thymocytes enhances positive selection and induces proliferation and apoptosis in vitro. Oncogene (2000) 0.92
Mnt: a novel Max-interacting protein and Myc antagonist. Curr Top Microbiol Immunol (1997) 0.89
Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells. Mol Cell Biol (2006) 0.88
Inhibition of cell growth and apoptosis by inducible expression of the transcriptional repressor Mad1. Exp Cell Res (2000) 0.88
Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J Immunol (2002) 0.87
c-myc gene expression and activation of human thymocytes. Thymus (1987) 0.76
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood (2004) 2.38
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol (2004) 2.12
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res (2008) 1.51
A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J Immunol (2004) 1.44
The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol (2009) 1.39
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol (2009) 1.32
Of Myc and Mnt. J Cell Sci (2006) 1.31
Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27
HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell-surface MHC-I. Cell Host Microbe (2007) 1.26
Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol (2005) 1.25
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol (2007) 1.24
Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses. Eur J Immunol (2007) 1.18
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol (2013) 1.16
IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol (2008) 1.14
Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene (2002) 1.12
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother (2010) 1.10
OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. J Immunol (2003) 1.06
IL-18 bridges innate and adaptive immunity through IFN-gamma and the CD134 pathway. J Immunol (2006) 1.03
Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol (2007) 1.03
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol (2009) 1.03
OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet. J Immunol (2007) 1.02
OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells. Eur J Immunol (2006) 1.00
Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol (2007) 1.00
Activities of N-Myc in the developing limb link control of skeletal size with digit separation. Development (2007) 0.99
A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis. Proc Natl Acad Sci U S A (2012) 0.93
Mnt transcriptional repressor is functionally regulated during cell cycle progression. Oncogene (2005) 0.92
OX40 (CD134) and OX40L. Adv Exp Med Biol (2009) 0.92
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med (2009) 0.91
Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. Eur J Immunol (2012) 0.91
Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg (2002) 0.91
4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology (2004) 0.91
The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother (2011) 0.90
Development of human gene reporter cell lines using rAAV mediated homologous recombination. Biol Proced Online (2007) 0.89
OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol (2009) 0.89
Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells. Mol Cell Biol (2006) 0.88
Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. PLoS One (2012) 0.88
OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J Immunol (2010) 0.87
Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis. J Immunol (2005) 0.87
Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol (2007) 0.85
Sequential and coordinated actions of c-Myc and N-Myc control appendicular skeletal development. PLoS One (2011) 0.83
Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy. Immunology (2012) 0.83
The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunol Immunother (2009) 0.82
Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II. Hum Mol Genet (2012) 0.82
The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. Hum Mol Genet (2009) 0.81
Differential regulation of N-Myc and c-Myc synthesis, degradation, and transcriptional activity by the Ras/mitogen-activated protein kinase pathway. J Biol Chem (2011) 0.80
CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease. Biol Blood Marrow Transplant (2004) 0.79
Expression and function of the OX40/OX40L costimulatory pair during herpes stromal keratitis. J Leukoc Biol (2006) 0.79
OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas. Am J Surg (2008) 0.78
MYC needs MNT. Cell Cycle (2013) 0.76
A repressor protein, Mnt, is a novel negative regulator of vascular smooth muscle cell hypertrophy by angiotensin II and neointimal hyperplasia by arterial injury. Atherosclerosis (2013) 0.76
Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. Cancer Immunol Immunother (2014) 0.76
Antipsychotic medications and diabetes mellitus. Director (2003) 0.75
Boosting T cell costimulation in cancer: the possibilities seem endless. Int Rev Immunol (2003) 0.75
Changes in the nursing facility-hospital interface after the prospective payment system: the effects on patients with infections in the post-acute care setting. J Am Med Dir Assoc (2003) 0.75